Vivani Medical, Inc. (VANI) stock intrinsic value fair value estimate & owner earnings analysis

Vivani Medical is a clinical-stage company developing miniature, removable drug implants built on its NanoPortal technology, a titanium-oxide membrane of nanotubes designed to release a drug steadily for six months or longer. Its lead program is NPM-139, a semaglutide implant for chronic weight management intended to be placed under the skin once or twice a year. The first human study of the platform (LIBERATE-1, an exenatide implant) met its safety and tolerability goals in 2025, and the Phase 1 study of NPM-139 (SLIM-1) enrolled and dosed all 20 participants by mid-2026, with top-line data expected in November 2026 and a Phase 2 dose-ranging study planned for 2027. Other programs are NPM-133 (semaglutide for type 2 diabetes), NPM-115 (exenatide for obesity) and OKV-119, an exenatide implant for cats and dogs licensed to Okava Pharmaceuticals. The company also owns Cortigent, the neurostimulation business inherited from its 2022 merger with Second Sight, which has signed an agreement to merge into Nasdaq-listed ClearOne, leaving Vivani with roughly 59% to 68% of the combined company, subject to a $10 to $15 million financing and shareholder approvals. The company has no revenue. Measured as the cash an owner could actually take out (operating cash flow with working-capital swings removed, stock compensation treated as a cost, and all equipment spending treated as necessary because there are no sales to grow into), the business has consumed between $20.6 million and $27.6 million a year since the Second Sight merger, or about $0.43 to $0.54 per share. The typical year over 2022 to 2025 is a loss of about $0.47 per share, and the first half of 2026 ran at a similar pace (operating cash outflow of $12.2 million). Years before 2021 under this company's filings describe Second Sight's retinal implant business and are not relevant to the business as it exists today. Spending has been paid for by repeated share sales: diluted shares rose from about 33 million in 2021 to about 87 million by mid-2026, much of it bought by an entity affiliated with one of the company's independent directors under tranche agreements signed in 2025 (about $12.6 million of those tranches were scheduled for 2026). Cash, including restricted cash, was $20.8 million at June 30, 2026, and the company said in March 2026 that its cash would fund plans into mid-2027. The largest fixed obligation is a ten-year lease on a 43,645 square foot building in Alameda, California, running to September 2033, carried at about $17.9 million. We only give credit for earnings power that can be traced to something that exists today: a contract, a product on sale, a demonstrated record. Vivani has none of these yet. The July 2026 agreement with Novo Nordisk lets Novo evaluate NPM-139 and the NanoPortal technology, but it is non-exclusive and has no disclosed payments, so we give it no value, though it is a genuine sign of interest. Even on a smooth path, NPM-139 would need Phase 2 and Phase 3 trials before any approval, which would be well into the 2030s and would require far more money than the company has, so almost all of today's cash will be spent before any product earns anything. Bear case (about -$0.16 per share): SLIM-1 data in November 2026 does not lead to a partner, the Novo evaluation ends, the director-affiliated funding stops after the committed tranches, and the ClearOne merger fails its financing condition. The company spends its remaining cash by mid-2027 and winds down. The Alameda lease still has more than six years to run, and with little left to set against it the company would owe roughly $14 million more than it is worth. A shareholder's liability is limited to the amount invested, but this case means nothing would be left for shareholders. Base case ($0.00 per share): SLIM-1 reads out, the Cortigent merger closes, and Vivani raises new money to start Phase 2 in 2027. Today's cash is spent on the trials, the Alameda building stays in use as the manufacturing site, and the lease is simply part of running the program. Because no product revenue or partnership payment is contracted, the program adds nothing we can count, and existing shareholders' stake is diluted by each new raise. What remains for today's owner is essentially nothing. Bull case (about $0.14 per share): SLIM-1 succeeds, Phase 2 starts on schedule, the ClearOne merger closes at the top of its financing range so that Vivani's majority stake carries a look-through share of roughly $8 million of new cash (locked up for one to two years), and Okava earns the $5 million of regulatory milestones added in April 2025 for its dog weight-management program. Those contracted and signed items, discounted at 6% a year, come to about $12 million, or roughly $0.14 per share. We do not count any licensing income from Novo Nordisk or anyone else, because no such agreement with payment terms exists. These values are low not because the technology has failed, but because a clinical-stage company is worth, to its current owners, only what it can contractually collect, and Vivani has not yet converted scientific progress into contracts. A disclosed partnership with real upfront and milestone payments, or an approval, would change the picture materially and would be the reason to revisit these figures. Until then, the business depends on continued share sales to survive, and each sale reduces what an existing share owns. The margin-of-safety price of about $0.05 applies only once such an agreement is signed, and leaves room for the long, expensive and uncertain path from Phase 1 data to a product on the market.